Ironwood Pharmaceuticals is trading 5% down now at $4.10 after second-quarter revenue missed estimates.
- Investors continued weighing mixed second-quarter results reported August 6.
- Management raised 2026 LINZESS and total-revenue guidance, while quarterly revenue of $113.04 million missed estimates by $1.68 million.
- Broader markets are only modestly mixed, with the decline appearing primarily tied to earnings digestion rather than a market-wide selloff.